

RELEVANT EVENT

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley del Mercado de Valores*), Grifols, S.A. (the “**Company**”) hereby notifies the acquisition of 21.30%, by means of the subscription of a capital increase with the exclusion of the preemptive rights, of the biotechnological company TiGenix N.V. (“**TiGenix**”), listed at the NYSE Euronext Brussels (TIG), based in Leuven, and with commercial offices in Madrid and Sittard-Gellen (the Netherlands).

This investment has been carried out through Gri-Cel, S.A., a 100% owned-subsiary of Grifols, which corporate purpose consists in the investment and management of companies devoted to the development of advanced therapies and personalized medicine.

TiGenix is a leading cell therapy company, which obtained the first approval in Europe for an advanced therapy product named ChondroCelect.

TiGenix is the 100% shareholder of TiGenix, S.A. (formerly Cellerix, S.A.), a company dedicated to the research and development of therapies based on adipose derived stem cells. A Phase III trial in an advanced stage is currently being performed for the treatment of perianal fistulas in patients with Crohn’s disease (“**Cx601**”). Cx601 has been designated as an Orphan Drug by the European Medicines Agency.

The agreement with TiGenix foresees the appointment of two board members by Grifols and the preferential right to negotiate the development and commercialization of all products owned by TiGenix (except for ChondroCelect).

The price agreed for the acquisition of 21.30% of TiGenix’ share capital is EUR 12 million.

Barcelona, 19 November 2013

Raimon Grifols Roura
Secretary to the Board of Directors